Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rebecca Gregory"'
Autor:
Conor Hugh O’Neill, Stuart McIlwaine, Caroline Forde, Johnny Cash, Bode Oladipo, Conor Braniff, Therese McCartney, Rebecca Gregory
Publikováno v:
Posters.
Introduction The emergence of checkpoint inhibitor immunotherapy (IO) has revolutionised outcomes for patients with metastatic melanoma, with significantly improved response rates and survival shown in clinical trials. This treatment modality is howe
Autor:
Rebecca Gregory, Sarah Brown, Laura Moss, Kate Newbold, Glenn D. Flux, Jonathan Wadsley, Andrew J. Hall, Yong Du, Louise Flanagan, Hannah Buckley, Kate Farnell, David Gonzalez de Castro
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer
Hall, A, Buckley, H L, Flanagan, L, Gonzalez de Castro, D, Farnell, K, Moss, L, Gregory, R, Newbold, K, Du, Y, Flux, G & Wadsley, J 2019, ' Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial ', BMC Cancer, vol. 19, 582 . https://doi.org/10.1186/s12885-019-5541-4
BMC Cancer
Hall, A, Buckley, H L, Flanagan, L, Gonzalez de Castro, D, Farnell, K, Moss, L, Gregory, R, Newbold, K, Du, Y, Flux, G & Wadsley, J 2019, ' Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial ', BMC Cancer, vol. 19, 582 . https://doi.org/10.1186/s12885-019-5541-4
Background Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival. Whilst Sorafenib and Len
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b29fc577b075922d29935c27350867
Autor:
Joy D. Fisher, Louise B. Grochow, Lyndon Kim, Rebecca Gregory, Stuart A. Grossman, T L Chen, Steven Piantadosi, Fred Hochberg
Publikováno v:
Cancer Chemotherapy and Pharmacology. 42:118-126
Background: High grade astrocytomas remain uniformly fatal despite aggressive surgery and radiotherapy. As existing chemotherapeutic agents are of limited benefit, clinical trials are underway to screen new drugs, such as 9-aminocamptothecin (9-AC),